Skip to main content
. 2024 Apr 2;47(9):2339–2349. doi: 10.1007/s40618-024-02320-7

Table 3.

Adverse event rates recorded in both study groups during the follow-up period. Data are presented as n (%)

Adverse events All patients (N = 31) No treatment (N = 14) Exenatide (N = 17) (N = 17) p-value
Gastrointestinal 9 (29.0) 0 (0) 9 (52.9)  < 0.001
Neuropsychiatric 3 (9.7) 0 (0) 3 (17.6) 0.1
Other 9(29.0) 6 (42.8) 3 (17.6) 0.12
At least one AE 18 (58.1) 6 (42.8) 12 (70.6) 0.12